Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

Janus Kinase inhibitors are effective and have an acceptable safety profile for treating moderate to severe Ulcerative Colitis.

Cyclosporin is effective in treating dog skin diseases and has fewer side effects compared to other treatments.

JAK inhibitors are effective for treating moderate-to-severe alopecia areata.

Ruxolitinib cream effectively targets and treats inflammatory skin diseases.

Upadacitinib can cause hypersensitivity that worsens ulcerative colitis symptoms.

Cancer patients treated with immune checkpoint inhibitors may develop alopecia, but some hair regrowth is possible with treatment.

PX-12 may help treat psoriasis by blocking inflammation and cell death.

Baricitinib shows promise for treating various skin conditions beyond alopecia areata.

Baricitinib reduces inflammation and mitochondrial damage in skin cells.

Imiquimod cream activates hair follicle stem cells and causes early hair growth by changing immune cells and certain protein expressions.

Using old drugs for new uses can help treat rare immune deficiencies.

The drug IPI-926 is safe at 160 mg daily and may help treat certain tumors, especially basal cell carcinoma.

Ixekizumab helps improve life quality, physical ability, and work performance in patients with psoriatic arthritis who haven't used biologic drugs before.

Most patients successfully switched from the original adalimumab to a biosimilar with few reverting due to reduced effectiveness or side effects.

JAK inhibition reduces autoimmune issues in Down syndrome.

Tofacitinib was more effective than apremilast in treating hair loss in a mouse model of alopecia areata.

Tofacitinib effectively treated a woman's complex autoimmune and autoinflammatory disorders.

Upadacitinib effectively improved severe atopic dermatitis and alopecia universalis in a 29-year-old man.

ICI therapy increases the risk of gastrointestinal and endocrine issues in psoriasis patients.

Biologics, especially Dupilumab, are effective and safe for treating severe childhood eczema.

CAR-T cell therapy shows promise for treating autoimmune disorders but faces challenges like complex manufacturing and limited tissue penetration.

Controlled delivery of specific RNA and IL-4 restored hair growth in mice with autoimmune alopecia.

JAK inhibitors are effective in treating various immune-related diseases, not just rheumatoid arthritis.

Actemra is approved for a specific artery condition, HIV treatment adherence has improved, women may pay more for a hair loss product, and incorrect dosing of blood thinners can be risky.

Cyclosporine effectively treated a woman's stubborn skin condition.

Transplant patients on immunosuppressive medications have a higher risk of skin cancer, and managing this involves balancing medication with cancer risk.

A humanized CXCL12 antibody may delay and treat alopecia areata by altering the immune response.